HUTCHMED
Update in progressHCM (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
HUTCHMED (China) Limited discovers, develops, and commercializes targeted cancer therapies and immunotherapies for cancer and immune diseases. Headquartered in Hong Kong, it operates in Hong Kong, the U.S., and globally. Core drugs include Fruquintinib (VEGFR inhibitor) for CRC and other cancers; Savolitinib (MET inhibitor) for NSCLC and RCC; Surufatinib; Sovleplenib; Tazemetostat; Fanregratinib; Ranosidenib. It also develops HMPL-760 and HMPL-506 and collaborates with major partners.
Company score
- Sentiment
- 0.12
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.10
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationHong Kong
- CEOMr. Chig Fung Cheng BEc, CA
- Founded2000
- Employees1,790
- Websitewww.hutch-med.com
Identifiers
- ISINUS44842L1035
- FIGIBBG00B6VCGJ1
- LEI2138006X34YDQ6OBYE79
- CUSIP44842L103
- CIK0001648257